NasdaqCM - Nasdaq Real Time Price USD

enVVeno Medical Corporation (NVNO)

3.6100

-0.1400

(-3.73%)

At close: May 30 at 4:00:00 PM EDT

3.6100

0.00

(0.00%)

After hours: May 30 at 4:04:05 PM EDT

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as ...

ACCESS Newswire 12 days ago

NVNBW

NVNO
-3.73%

NVNOW
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits Company ...

ACCESS Newswire 18 days ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Cash Burn of $4.0 million in Q1 remains in line with projected quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the initiation of the enVVe pivotal trial FDA decision ...

ACCESS Newswire 30 days ago

NVNBW

NVNO
-3.73%

NVNOW
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

IRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the VenoValve® will be featured ...

ACCESS Newswire last month

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company ...

ACCESS Newswire last month

NVNBW

NVNO
-3.73%

NVNOW
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

IRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced its abstract has been accepted for ...

ACCESS Newswire last month

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly range Cash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the initiation of the enVVe pivotal ...

ACCESS Newswire 2 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 /enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today ...

ACCESS Newswire 3 months ago

NVNBW

NVNO
-3.73%

NVNOW
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators. PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025. IRVINE, CA ...

ACCESS Newswire 3 months ago

NVNBW

NVNO
-3.73%

NVNOW
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months. 78% of subjects maintained a clinically meaningful benefit of more than 3 points ...

ACCESS Newswire 3 months ago

NVNBW

NVNO
-3.73%

NVNOW
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects ...

ACCESS Newswire 5 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial Access the Recap Website Here! IRVINE, CA / ACCESSWIRE ...

ACCESS Newswire 5 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st ...

ACCESS Newswire 6 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) ...

ACCESS Newswire 6 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4 GLP study for enVVe® transcatheter-based replacement venous valve underway; On track to file IDE approval for pivotal trial ...

ACCESS Newswire 6 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

First wave of implants successfully completed with updated delivery system performing very well Company on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA / ACCESSWIRE / October 28, 2024 / enVVeno Medical ...

ACCESS Newswire 6 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the pricing of an underwritten public ...

ACCESS Newswire 7 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Corporation Announces Proposed Public Offering

IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that it is proposing to offer and sell, ...

ACCESS Newswire 7 months ago

NVNBW

NVNO
-3.73%

NVNOW
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

MedTech Marketing Leader with Significant New Product Launch Experience for Cardiovascular Devices Key Addition to Commercial Team as Company Begins Planning for the VenoValve Monetization Several Upcoming Company Milestones Planned for Q4 of 2024 ...

ACCESS Newswire 8 months ago

NVNBW

NVNO
-3.73%

NVNOW

Performance Overview

Return	NVNO	S&P 500 (^GSPC)
YTD	+19.54%	+0.51%
1-Year	-25.10%	+12.92%
3-Year	-13.12%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

enVVeno Medical Corporation (NVNO)

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

enVVeno Medical Corporation Announces Proposed Public Offering

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

Performance Overview